Advertisement

Topics

Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA ...

03:00 EST 18 Jan 2018 | BioMedReports - Blog

BHV-5000 is a low trapping, potent  N-methyl-D-aspartate (NMDA) receptor antagonist licensed to Biohaven from AstraZeneca.  BHV-5000 was previously advanced into a Phase 1 clinical

Read more...

Original Article: Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA ...

NEXT ARTICLE

More From BioPortfolio on "Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...